Wellington Management Group LLP Has $1.43 Billion Stake in Boston Scientific Corporation $BSX

Wellington Management Group LLP lowered its stake in Boston Scientific Corporation (NYSE:BSX) by 55.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,653,441 shares of the medical equipment provider’s stock after selling 17,996,024 shares during the quarter. Wellington Management Group LLP owned 0.99% of Boston Scientific worth $1,430,615,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new stake in Boston Scientific in the second quarter worth $2,089,937,000. Edgewood Management LLC acquired a new position in shares of Boston Scientific during the second quarter valued at about $746,655,000. Parnassus Investments LLC boosted its position in shares of Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after purchasing an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP boosted its position in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Boston Scientific by 133.5% in the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after buying an additional 2,823,744 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on BSX shares. TD Cowen decreased their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Royal Bank Of Canada decreased their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. National Bank Financial set a $115.00 target price on Boston Scientific in a report on Monday, February 2nd. Finally, Citigroup reduced their price target on shares of Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $108.00.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $69.15 on Friday. The stock has a 50 day moving average of $82.47 and a 200 day moving average of $93.39. The company has a market capitalization of $102.61 billion, a price-to-earnings ratio of 35.64, a PEG ratio of 0.96 and a beta of 0.69. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the firm earned $0.70 earnings per share. The business’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.